Bryant Furlow

Although uncommon, this side effect of radiation with adjuvant drug therapy is unpredictable, sometimes delayed, and can occur with administration of antibiotics and other drugs as well as chemotherapy.

The journal Science named cancer immunotherapy as “the breakthrough of the year”; but challenges still remain to overcome tumor immune suppression and genomic instability.

Helping patients understand that CAM products and dietary supplements may impede their cancer treatment is an essential part of patient education.

Soy and soy isoflavones are alleviating skin and lung toxicities from thoracic radiotherapy in preclinical study models; however, researchers stress the need for further studies.

Respiratory motion management reduces radiation exposure to nontarget tissues in patients undergoing treatment of cancers in the chest and abdomen.

These tools can help clinicians determine which treatments are ideal and explain to patients what their best options are and why.

Is the pain ineffectively managed baseline pain or is it breakthrough pain? This discussion reviews how to determine the answer and what to do next.

Management of bone metastasis is an increasingly common challenge. Palliative radiotherapy is proving to effectively relieve pain and improve quality of life for patients.

Few patients with HCC are candidates for curative treatment at diagnosis. However, a new study demonstrated that stereotactic body radiotherapy…

The key to managing this late effect is patient education because it can manifest long after patients complete radiotherapy.